Andros Mannenkliniek, Arnhem, the Netherlands.
J Sex Med. 2011 Oct;8(10):2912-23. doi: 10.1111/j.1743-6109.2011.02462.x. Epub 2011 Aug 30.
Patients and physicians consider a rapid onset of action to be an important attribute of oral pharmacotherapy for erectile dysfunction.
To investigate the time to onset of action of a new orodispersible tablet (ODT) formulation of vardenafil.
A post hoc integrated analysis was performed on data from two 12-week, double-blind, multicenter, randomized, parallel-group, placebo-controlled phase III trials of 10 mg vardenafil ODT. Data for the vardenafil film-coated tablet were generated from a retrospective integrated analysis at week 12 of four double-blind, multicenter, randomized, parallel-group, fixed-dose, placebo-controlled phase III trials. Time intervals (in 15-, 30-, and 60-minute increments, up to ≥6 hours after study medication intake) were determined for the period between dosing and start of sexual activity (with the intention of intercourse).
The total number of sexual intercourse attempts and Sexual Encounter Profile question 3 (SEP3) success rates were calculated per time interval.
Within 15 minutes postdosing, mean per-patient SEP3 success rates were 62.5% (vardenafil ODT) vs. 29.4% (placebo), with corresponding overall SEP3 success rates of 59.8% and 38.2%. In this time interval, 5.3% vs. 2.8% of all sexual activity attempts were initiated by subjects taking vardenafil ODT (n = 89) or placebo (n = 62), respectively. At 16-30 minutes postdosing, SEP3 success rates were 65.3% and 32.6% (mean per-patient) and 70.2% and 51.0% (overall) for vardenafil ODT vs. placebo, respectively, with a corresponding 10.4% and 8.7% of all sexual activity attempts being made by subjects taking vardenafil ODT (n = 170) or placebo (n = 118). Comparable results were observed for vardenafil 10 and 20 mg film-coated tablet at corresponding time intervals.
Vardenafil ODT shows a rapid onset of action comparable with that of vardenafil film-coated tablet. In those men who begin sexual activity within 30 minutes after dosing, the majority of sexual attempts lead to successful intercourse.
患者和医生认为,治疗勃起功能障碍的口服药物能迅速起效是一个重要的属性。
研究一种新的伐地那非口腔分散片(ODT)制剂的起效时间。
对两项为期 12 周、双盲、多中心、随机、平行分组、安慰剂对照的 III 期临床试验中 10mg 伐地那非 ODT 的数据进行了事后整合分析。伐地那非薄膜片的数据来源于四项双盲、多中心、随机、平行分组、固定剂量、安慰剂对照 III 期临床试验中第 12 周的回顾性整合分析。从服药后到开始性活动(意向性交)的时间间隔(每 15 分钟、30 分钟和 60 分钟递增,最长至≥6 小时)确定。
根据每个时间间隔,计算总的性交尝试次数和性经历概况问卷 3(SEP3)成功率。
在服药后 15 分钟内,伐地那非 ODT 组的每位患者 SEP3 成功率为 62.5%(n=89),安慰剂组为 29.4%(n=62),相应的总体 SEP3 成功率分别为 59.8%和 38.2%。在这一时间间隔内,5.3%的性活动尝试由服用伐地那非 ODT 的患者(n=89)发起,而 2.8%的性活动尝试由服用安慰剂的患者(n=62)发起。在 16-30 分钟时,伐地那非 ODT 组的 SEP3 成功率为 65.3%和 32.6%(每位患者的平均)和 70.2%和 51.0%(总体),而安慰剂组的 SEP3 成功率为 65.3%和 32.6%(每位患者的平均)和 70.2%和 51.0%(总体),而相应的性活动尝试中,10.4%和 8.7%由服用伐地那非 ODT 的患者(n=170)或安慰剂(n=118)发起。在相应的时间间隔内,观察到伐地那非 10mg 和 20mg 薄膜片有类似的起效时间。
伐地那非 ODT 起效迅速,与伐地那非薄膜片相当。在那些在服药后 30 分钟内开始进行性活动的男性中,大多数性尝试都能成功进行性交。